Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study

Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study

Pharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence. A number of genetic variants within the PCSK9 gene locus have been...

Full description

Bibliographic Details
Main Authors: Isabela Bensenor, Kallyandra Padilha, Isabella Ramos Lima, Raul Dias Santos, Gilles Lambert, Stéphane Ramin-Mangata, Marcio S Bittencourt, Alessandra C Goulart, Itamar S. Santos, Jose G Mill, Jose E Krieger, Paulo A. Lotufo, Alexandre C. Pereira
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Genetics
Subjects:
genetic variation
genome-wide association study
atherosclerosis
proprotein convertase subtilisin/kexin type 9
colocalization analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.728526/full

Similar Items

Similar Items